Chemcrux Enterprises has notified BSE Limited of an upcoming Board of Directors meeting, pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting is scheduled for Thursday, May 14, 2026, at 11:30 A.M. at the company's Registered Office located at 330, Trivia Complex, Natubhai Circle, Racecourse Road, Vadodara-390007, Gujarat.

Key Agenda Items

The Board Meeting will address several significant matters pertaining to the company's financial performance and shareholder returns. The following key agenda items have been outlined in the intimation:

The Board Meeting will be preceded by an Audit Committee Meeting on the same day, May 14, 2026, in line with standard corporate governance practices.

Trading Window Closure

In accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and consistent with an earlier intimation dated March 26, 2026, the company had closed the Trading Window for designated persons from April 1, 2026. The trading window close period will conclude 48 hours after the financial results for the quarter and year ended March 31, 2026, are made public on May 14, 2026.

The intimation was signed by Dipika Rajpal, Company Secretary & Compliance Officer, on May 7, 2026.

Chemcrux Enterprises Limited , a key player in the bulk drug intermediates sector, has announced significant corporate developments and financial results for the second quarter of fiscal year 2025-26.

New CFO Appointment

The company's Board of Directors has approved the appointment of Ms. Mruga Gajjar as the new Chief Financial Officer (CFO) and Key Managerial Personnel, effective November 6, 2025. Ms. Gajjar brings a wealth of experience to her new role:

• Over 11 years of experience with CA firms
• 3 years in accounting and finance functions at an Electrical EPC company
• 4 months as Senior Executive - Accounts & Finance at Chemcrux Enterprises

Ms. Gajjar's educational background includes:

• Bachelor's degree in Accounting & Financial Management from M.S. University Vadodara
• Master's degree in Commerce from IGNOU
• Cleared CA Intermediate examination

Financial Performance

The Board of Directors has approved the unaudited standalone and consolidated financial results for Q2 and H1 FY2026. Here are the key highlights of the consolidated financial results:

The company's revenue from operations for Q2 FY2026 stood at INR 1,770.63 lacs, showing a marginal decrease compared to INR 1,775.62 lacs in the same quarter of the previous year. The profit for the period in Q2 FY2026 was INR 21.29 lacs, down from INR 114.75 lacs in Q2 FY2025.

For the half-year ended September 30, 2025, Chemcrux Enterprises reported a total income of INR 3,531.55 lacs, slightly lower than the INR 3,551.15 lacs recorded in H1 FY2025. The profit for the period in H1 FY2026 was INR 30.55 lacs, compared to INR 238.57 lacs in the corresponding period of the previous year.

The company's earnings per share (EPS) for Q2 FY2026 stood at Rs. 0.14, down from Rs. 0.77 in Q2 FY2025. For H1 FY2026, the EPS was Rs. 0.21, compared to Rs. 1.61 in H1 FY2025.

The Board meeting, which commenced at 11:30 A.M. and concluded at 01:45 P.M., also reviewed and approved these financial results as recommended by the Audit Committee.

Chemcrux Enterprises continues to focus on its core business of manufacturing and processing bulk drug intermediates. The company's management is committed to navigating the current market conditions and working towards improved performance in the coming quarters.